Prof. Georgios Giamas obtained his Biology degree (BSc) at the National and Kapodistrian University of Athens in Greece. He then obtained his Doctoral degree (PhD - Magna Cum Laude) at the University of Ulm (Germany). Following postdoctoral work at the University of Ulm, he moved to Imperial College London in 2007, working as a Research Associate in the Division of Surgery and Cancer. In 2011, he was awarded the Imperial College's Junior Research Fellowship, and in 2012 he was appointed as a Research Team Leader. In July 2015, he became a Reader (Associate Professor) in Cell Signaling at the University of Sussex. Since May 2018, he has been a Professor at the Department of Biochemistry and Biomedicine at the University of Sussex while holding an honorary contract (Visiting Professor) at Imperial College. He was the Director of Research and Knowledge Exchange (DRaKE) at the School of Life Sciences between May 2019 and April 2020 and the UOA5 lead for REF2021. He is also an Associate Fellow of the Higher Education Academy and has served as the Designated Individual (DI) under the Human Tissue Act at the School of Life Sciences from June 2017 to May 2019. In addition, he served as Head of the Department for Biochemistry and Biomedicine at the School of Life Sciences from July 2020 to August 2022. He is also the Founder and Chief Scientific Advisor of Stingray Bio, a biotech spin-out company developing small-molecule inhibitors for cancer therapy.
Prof. Georgios Giamas obtained his Biology degree (BSc) at the National and Kapodistrian University of Athens in Greece. He then obtained his Doctoral degree (PhD - Magna Cum Laude) at the University of Ulm (Germany). Following postdoctoral work at the University of Ulm, he moved to Imperial College London in 2007, working as a Research Associate in the Division of Surgery and Cancer. In 2011, he was awarded the Imperial College's Junior Research Fellowship, and in 2012 he was appointed as a Research Team Leader. In July 2015, he became a Reader (Associate Professor) in Cell Signaling at the University of Sussex. Since May 2018, he has been a Professor at the Department of Biochemistry and Biomedicine at the University of Sussex while holding an honorary contract (Visiting Professor) at Imperial College. He was the Director of Research and Knowledge Exchange (DRaKE) at the School of Life Sciences between May 2019 and April 2020 and the UOA5 lead for REF2021. He is also an Associate Fellow of the Higher Education Academy and has served as the Designated Individual (DI) under the Human Tissue Act at the School of Life Sciences from June 2017 to May 2019. In addition, he served as Head of the Department for Biochemistry and Biomedicine at the School of Life Sciences from July 2020 to August 2022. He is also the Founder and Chief Scientific Advisor of Stingray Bio, a biotech spin-out company developing small-molecule inhibitors for cancer therapy.